FeesSafety
Pluang+

Rigel Pharmaceuticals shifts focus to oncology with new product VEPPANU targeting $1B breast cancer market.

Market News
22 Oct 2026, 14:19 WIB
Seeking Alpha
View Source
Bullish
Rigel Pharmaceuticals shifts focus to oncology with new product VEPPANU targeting $1B breast cancer market.

Rigel Pharmaceuticals is transitioning from its immune thrombocytopenia (ITP) roots to become a multi-product oncology company. Its new drug VEPPANU is launching in the U.S. to address a $1 billion market for ESR1-mutated breast cancer, although early sales are not yet reflected in current forecasts. Rigel’s stock trades at a discount compared to sector averages despite strong sales growth and high profit margins in its base business. Investors will be watching upcoming Q3 results for updates on key products like TAVALISSE, GAVRETO, REZLIDHIA, and the initial market uptake of VEPPANU.

Regarding Rigel Pharmaceuticals, here is Pluang's health sector market snapshot as of Oct 22, 2026 18:01 WIB: Out of 150 priced US health stocks, 68 rose and 75 fell today. Notable movers include CRSP at USD 49.34 with a 1-day change of -2.30% and 100% buy order activity, HIMS at USD 28.71 down 1.71% with 100% buy order activity, and MRNA at USD 241.61 down 1.71% with 57% sell order activity. The most notable figure is CRSP's typical hold time on Pluang of 78 days.

More News

European Commission approves RASONQUE for metastatic pancreatic cancer treatment

European Commission approves RASONQUE for metastatic pancreatic cancer treatment

The European Commission has approved RASONQUE (daraxonrasib), the first broad RAS-targeted oral medicine for adults with metastatic pancreatic adenocarcinoma who have had prior systemic therapy. This approval covers patients with or without identifie...

Market News
Bullish
54 minutes ago
SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE, a European leader in multi-technical services, has acquired Dutch company Duflex B.V. to enhance its industrial automation, machine building, and robotics capabilities. Duflex, with 26 employees and €8 million revenue in 2025, specializes in ta...

Company Fundamentals
Bullish
1 hour ago
Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel Développement SAS disclosed that it repurchased a total of 3,878 of its own shares between November 9 and November 13, 2026. The average purchase price during this period was approximately €34.67 per share. This buyback is part of an authorized...

Company Fundamentals
Neutral
1 hour ago
Rexel repurchases 3,878 own shares at an average price of €34.67 in early November 2026

Rexel repurchases 3,878 own shares at an average price of €34.67 in early November 2026

Rexel Développement SAS announced it bought back a total of 3,878 of its own shares between November 9 and 13, 2026, at an average price of €34.67 per share. This share repurchase is part of the authorization granted by its shareholders to operate on...

Company Fundamentals
Neutral
1 hour ago
SPIE acquires Duflex B.V. to boost industrial automation and robotics expertise in the Netherlands.

SPIE acquires Duflex B.V. to boost industrial automation and robotics expertise in the Netherlands.

SPIE, a leading European multi-technical services company, has acquired Duflex B.V., a Dutch firm specializing in industrial automation, machine construction, and robotics. This acquisition strengthens SPIE's capabilities in the industrial services v...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App